Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

This trial is evaluating a drug called tagraxofusp as a maintenance therapy (ongoing treatment to prevent relapse) after a stem cell transplant in patients with certain blood cancers — specifically AML (acute myeloid leukemia), MDS (myelodysplastic syndrome), myelofibrosis, or CMML — whose cancer cells carry a marker called CD123. **You may be eligible if...** - You are between 18 and 75 years old - You have AML, MDS, myelofibrosis, or CMML with CD123-positive cancer cells - You have recently undergone a stem cell (bone marrow) transplant - You have adequate organ function (heart, kidney, liver) - Your life expectancy is greater than 6 months **You may NOT be eligible if...** - Your cancer cells do not express the CD123 marker - You have serious organ dysfunction - You have active serious infections or graft-versus-host disease requiring high-dose steroids - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.